Open House Rebate Agreements Clobetasol
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Clobetasol, ATC D07AD01
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No estimated value or volume – revenue potential unknown. The agreement is non-exclusive and may be superseded by futur...
The agreement automatically terminates if a regular (competitive) rebate contract for the same substance comes into eff...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Apr 2028
- Provide pharmaceutical products with active substance Clobetasol (ATC D07AD01)
- Enter into non-exclusive rebate agreement with AOK Bayern
Show full summary
This is an open-house (non-competitive) model for non-exclusive rebate agreements on Clobetasol (ATC D07AD01) with AOK Bayern. All interested pharmaceutical companies that meet eligibility criteria can join. Contracts run from 01/05/2026 to 30/04/2028, with possibility of later joining until 03/03/2028. No estimated value provided. No award criteria (no selection). Eligibility requires a signed self-declaration of reliability. Submission can be in paper or electronic with qualified signature. Documents must be requested via the DTVP portal.
Risks
No estimated value or volume – revenue potential unknown. The agreement is non-exclusive and may be superseded by futur...
The agreement automatically terminates if a regular (competitive) rebate contract for the same substance comes into eff...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Eligibility: signed self-declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
Administrative
- Submission of signed contract, annex listing medicines, and self-declaration
- Submission via paper (2 original copies) or electronic with qualified electronic signature via DTVP portal
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open House Rebate Agreements Clobetasol
Non-exclusive rebate agreements for pharmaceutical products containing Clobetasol (ATC D07AD01). All eligible companies can join. Framework agreement with no guaranteed volume. Contract duration 24 months (01/05/2026-30/04/2028).
Location
Duration
Category
Award Criteria
Deadline
Award details
No award criteria – open-house model, no selection.
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Clobetasol, ATC D07AD01
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 15 Mar 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 181502-2026
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No estimated value or volume – revenue potential unknown. The agreement is non-exclusive and may be superseded by futur...
The agreement automatically terminates if a regular (competitive) rebate contract for the same substance comes into eff...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications